OrbiMed

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

2 Sept 2025

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.

OrbiMed

- Life Sciences
1(12 months)
orbimed.com
Update Information

More venture news

1 Apr 2026
Sona secures a £34m Series B led by N47 for workforce management software focussed on frontline businesses
Series BEnterprise
Giraffe360
26 Mar 2026
Giraffe360 secures a £7.5m Series B led by Cipio Partners for real estate marketing tech
Series BProperty
18 Feb 2026
FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform
Series BIndustrial

OrbiMed

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

More venture news

Sona secures a £34m Series B led by N47 for workforce management software focussed on frontline businesses

Giraffe360 secures a £7.5m Series B led by Cipio Partners for real estate marketing tech

FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform